MacroGenics gets that sinking feeling
Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.
MacroGenics pays for its ASCO exuberance
The company looks rash for promising Tamarack data at the conference, although at least vobra duo’s safety has improved.
MacroGenics muddies its key catalyst
Tamarack data are a 2024 catalyst, so why has MacroGenics brought forward a follow-on molecule?
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
A cancer pipeline cull from AbbVie
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
World Lung 2023 preview – Astra’s Tagrisso showdown
Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.
